Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

High-Affinity Mouse Monoclonal Antibodies to Glypican-3 (GPC3) for Research Use

Posted Jul 19 2012 8:00pm

Description of Invention:
Liver cancer is the fifth most common cancer in the world, with hepatocellular cancer (HCC) representing the preponderance of these liver cancers. As with many cancers, positive prognosis for a patient diagnosed with HCC correlates with the early detection of the disease. Unfortunately, HCC is usually detected at a late stage in its development, leading to poor prognosis for most patients. As a result, there is great interest and value in developing new agents which can detect the presence of HCC in a patient at an early stage.

Glypican-3 (GPC3) is a cell surface heparan sulfate glycoprotein that is expressed on the vast majority of HCC cells. The correlation between GPC3 expression and HCC makes GPC3 an attractive candidate for studying the disease progression and treatment of HCC. The presence, progression and treatment of this disease can potentially be monitored by tracking the level of expression of GPC3 on cells. This can be accomplished using monoclonal antibodies which recognize only GPC3, particularly the cell surface domain of the protein. This invention concerns the generation of several monoclonal antibodies that are specific for the cell surface domain of GPC3 (YP6, YP7, YP8, YP9 and YP9.1), and which can be used as research reagents for studying the role of GPC3 in HCC.

Applications:
Antibodies for use as research materials, including:
  • detection of cells that express GPC3 for monitoring HCC disease progression and treatment
  • immunostaining for tumor imaging
  • ELISA and immunohistochemistry applications
  • any other antibody-related research use, including immunoprecipitation, western blot analysis, etc.


Advantages:
  • Higher binding affinity (subnanomolar levels) than commercially available GPC3 antibodies such as 1G12
  • Recognition of cells with low levels of GPC3 expression
  • Able to bind to wild-type GPC3 (conjugated to heparan sulfate) better than the GPC3 core protein (lacking heparan sulfate)


Development Status:
  • Early-stage
  • In vitro data available


Inventors:
Mitchell Ho (NCI)
Yen T Phung (NCI)


Patent Status:
HHS, Reference No. E-136-2012/0
US, Application No. 61/654,232 filed 01 Jun 2012


Related Technologies:
US, Application No. 61/477,020 filed 19 Apr 2011, Reference No. E-130-2011/0
PCT, Application No. PCT/US2012/034186 filed 19 Apr 2012, Reference No. E-130-2011/0


Relevant Publication:
  1. Ho M, Kim H. [ PMID 21112773 ]
  2. Ho M. [ PMID 21942912 ]


Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize cancer diagnostics, isolation of circulating tumor cells, humanization and/or immunoconjugates. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov .


For Licensing Information Please Contact:
Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: mb715y@nih.gov
Phone: 301-435-2950
Fax: 301-402-0220


Ref No: 2462

Updated: 07/2012

Post a comment
Write a comment:

Related Searches